Abstract
Lysine specific demethylase 1 (LSD1) represents a promising epigenetic target in the treatment of Acute Myeloid Leukemia (AML) and inhibition of LSD1 has been shown to facilitate a response of AML cells to all-trans retinoic acid (ATRA). In this project, we have now modeled the effect of pharmacological or genetic inactivation of LSD1 in two different murine leukemia models based on the retroviral overexpression of either Hoxa9/Meis1 (H/M) or MN1. We transformed bone marrow cells from conditional LSD1 knock-out (KO) mice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
